[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

IN2012DN01981A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01981A
IN2012DN01981A IN1981DEN2012A IN2012DN01981A IN 2012DN01981 A IN2012DN01981 A IN 2012DN01981A IN 1981DEN2012 A IN1981DEN2012 A IN 1981DEN2012A IN 2012DN01981 A IN2012DN01981 A IN 2012DN01981A
Authority
IN
India
Prior art keywords
rgd
disease
diseases
proteins
granuloma
Prior art date
Application number
Inventor
Shankar Kumar
J Yun Tso
Naoya Tsurushita
Original Assignee
Gene Techno Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gene Techno Science Co Ltd filed Critical Gene Techno Science Co Ltd
Publication of IN2012DN01981A publication Critical patent/IN2012DN01981A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
IN1981DEN2012 2009-09-24 2010-09-22 IN2012DN01981A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27243809P 2009-09-24 2009-09-24
PCT/JP2010/067017 WO2011037271A1 (en) 2009-09-24 2010-09-22 Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN01981A true IN2012DN01981A (en) 2015-07-24

Family

ID=43796008

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1981DEN2012 IN2012DN01981A (en) 2009-09-24 2010-09-22

Country Status (9)

Country Link
US (1) US8617829B2 (en)
EP (1) EP2480665A4 (en)
JP (1) JP5781504B2 (en)
KR (1) KR101809761B1 (en)
CN (1) CN102712921B (en)
AU (1) AU2010299017B2 (en)
CA (1) CA2772230C (en)
IN (1) IN2012DN01981A (en)
WO (1) WO2011037271A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983616B1 (en) * 2013-04-08 2018-10-03 Regentys Corporation Method and composition for treating inflammatory bowel disease without colectomy
CA2980495A1 (en) 2015-04-20 2016-10-27 Consejo Superior De Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
JP6975722B2 (en) * 2016-11-18 2021-12-01 アステラス製薬株式会社 A novel anti-human MUC1 antibody Fab fragment
TWI795415B (en) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 A novel anti-human CEACAM5 antibody Fab fragment
MX2021004146A (en) 2018-10-10 2021-06-08 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
CA2370129A1 (en) 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
JP2003528322A (en) 2000-03-23 2003-09-24 グラクソ グループ リミテッド Methods for screening for inhibitors of osteopontin
JP2007106767A (en) * 2001-04-05 2007-04-26 Meneki Seibutsu Kenkyusho:Kk Anti-osteopontin antibody and use thereof
ATE412013T1 (en) 2001-04-05 2008-11-15 Immuno Biological Lab Co Ltd ANTI-OSTEOPONTIN ANTIBODIES AND USE THEREOF
EP1431310A4 (en) * 2001-09-25 2005-03-23 Immuno Biological Lab Co Ltd Recombinant anti-osteopontin antibody and use thereof
JPWO2004103403A1 (en) 2003-05-23 2006-07-20 株式会社 免疫生物研究所 Immunocompetent cell activation inhibitors and uses thereof
KR101475960B1 (en) 2006-10-26 2014-12-23 가부시키가이샤 진 테크노 사이언스 Antibody against RGD in amino acid sequence of extracellular matrix protein and production method and use of the same
WO2009131256A1 (en) * 2008-04-24 2009-10-29 Gene Techno Science Co., Ltd. Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof

Also Published As

Publication number Publication date
US20120219503A1 (en) 2012-08-30
JP5781504B2 (en) 2015-09-24
US8617829B2 (en) 2013-12-31
WO2011037271A1 (en) 2011-03-31
EP2480665A4 (en) 2013-04-03
CA2772230C (en) 2019-01-08
JP2013505702A (en) 2013-02-21
AU2010299017A1 (en) 2012-03-15
KR101809761B1 (en) 2017-12-15
CN102712921A (en) 2012-10-03
KR20120078725A (en) 2012-07-10
EP2480665A1 (en) 2012-08-01
CN102712921B (en) 2017-03-01
AU2010299017B2 (en) 2014-02-06
CA2772230A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
EP2388323A3 (en) Humanized anti-9 integrin antibodies and the uses thereof
NZ594315A (en) Antibody molecules having specificity for human ox40
EP4398255A3 (en) Methods, systems, and software for identifying bio-molecules with interacting components
NZ606587A (en) Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EA201300418A1 (en) ANTIBODIES TO THE HUMAN TWEAK AND VARIANTS OF THEIR APPLICATION
JO3375B1 (en) Human antibodies to human tnf-like ligand 1a (tl1a)
IN266863B (en)
IN2012DN01981A (en)
MX2019007708A (en) Novel anti-inflammatory agents.
WO2012048332A3 (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
UA115540C2 (en) Anti il-36r antibodies
TW200740844A (en) Novel MAdCAM antibodies
RU2016146486A (en) HUMANIZED ANTIBODIES AGAINST CD269 (BCMA)
MX2011011729A (en) Anti-il-17f antibodies and methods of use thereof.
WO2012118813A3 (en) Anti-il-6 receptor antibodies and methods of use
EP2037961A4 (en) Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
MY151045A (en) Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
JO3327B1 (en) Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4’-trifluormethylphenyl)- amide tablet formulations with improved stability
MX2009008608A (en) Monoclonal anti-cxcl13 antibodies.
MX2010006181A (en) Anti-human il-21 monoclonal antibodies.
NZ604643A (en) S100a4 antibodies and therapeutic uses thereof
NZ601271A (en) Cd127 binding proteins
EP2662091A3 (en) Anti-P-selectin antibodies and methods of using the same to treat inflammatory diseases
HRP20192006T1 (en) Antibodies specific to fcrn
WO2008110379A8 (en) Monoclonal antibodies for treatment of cancer